Trial Profile
A Phase 1/2, Open-Label, Uncontrolled, Multiple-Dose Escalation, Cohort Expansion And Extension Study To Evaluate The Safety, Tolerability, And Pharmacokinetics Of ASN001 In Subjects With Metastatic Progressive Castrate Resistant Prostate Cancer
Status:
Discontinued
Phase of Trial:
Phase I/II
Latest Information Update: 28 Feb 2023
Price :
$35
*
At a glance
- Drugs ASN 001 (Primary)
- Indications Adenocarcinoma; Prostate cancer
- Focus Adverse reactions; Therapeutic Use
- Sponsors Asana BioSciences; Kirilys Therapeutics
- 06 Mar 2018 Status changed from active, no longer recruiting to discontinued.
- 09 Aug 2017 Planned End Date changed from 31 Jul 2017 to 31 Aug 2017.
- 09 Aug 2017 Planned primary completion date changed from 31 Jul 2017 to 31 Aug 2017.